On February 21, 2019 Theravance Biopharma, Inc. (NASDAQ: TBPH) reported that management will participate in a fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019, at 9:00 a.m. ET (Press release, Theravance, FEB 21, 2019, View Source [SID1234533564]). The conference will take place February 27 – March 1 at the Lotte New York Palace Hotel.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live broadcast will be available by visiting the Investor Relations section of Theravance Biopharma’s website at www.theravance.com, under the Presentations & Events tab. Listeners are encouraged to visit the site at least 15 minutes prior to the scheduled presentation to register, download and install any necessary audio software. Audio replays will be available for 30 days following the presentation.

On February 21, 2019 ArQule, Inc. (Nasdaq: ARQL) reported it will report financial results for the fourth quarter and full year of 2018 before the market opens on Thursday, March 7, 2019 (Press release, ArQule, FEB 21, 2019, View Source [SID1234533535]). The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a general business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live webcast can be accessed in the "Investors and Media" section of our website, www.arqule.com, under "Events & Presentations." You may also listen to the call by dialing (877) 868-1831 within the U.S. or (914) 495-8595 outside the U.S. A replay will be available two hours after the completion of the call and can be accessed in the "Investors & Media" section of our website, www.arqule.com, under "Events and Presentations."

On February 21, 2019 Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) constructs, reported that its CEO, Dr. David Giljohann, will present a corporate update at the 12th Annual European Life Sciences CEO Forum being held February 25-26, 2019 at the Hilton Zurich Airport Hotel in Zurich, Switzerland (Press release, Exicure, FEB 21, 2019, View Source [SID1234533552]). The presentation will occur on Monday, February 25, 2019 at 12:00 pm GMT+1.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast will be available on the Investors section of Exicure’s website: www.exicuretx.com. The webcast will be archived for approximately 30 days following the event.

On February 21, 2019 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) reported that it will report its fourth quarter and year end 2018 financial results after market close on Thursday, February 28, 2019 (Press release, Rigel, FEB 21, 2019, View Source [SID1234533565]). Rigel senior management will follow the announcement with a live conference call and webcast at 5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial results and give a company update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Participants can access the live conference call by dialing (855) 892-1489 (domestic) or (720) 634-2939 (international) and using the Conference ID number 2257425. The conference call will also be webcast live and can be accessed from Rigel’s website at www.rigel.com. The webcast will be archived and available for replay for 30 days after the call via the Rigel website.

On February 21, 2019 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, reported that the company will release its operating and financial results for the transition period from October 1, 2018 to December 31, 2018 before the opening of U.S. markets on Monday, February 25, 2019 (Press release, Autolus, FEB 21, 2019, View Source [SID1234550833]). The transition period is necessary to accommodate the change in the company’s financial year end from September 30 to December 31.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Management will host a conference call at 8:00 a.m. ET/ 1:00pm GMT the same day to discuss the company’s financial results and provide an operational update. To listen to the webcast and view the accompanying slide presentation, please go to: View Source

The call may also be accessed by dialing 877-270-2148 (U.S.) or 412-902-6510 (international) and asking the operator to join the Autolus Therapeutics conference call. After the conference call, a replay will be available for one week. To access the replay, please dial 877-344-7529 (U.S.) or 412-317-0088 (international) and enter replay access code 10129000.